Why the study?
Anthracyclines carry a serious risk of cardiotoxicity and congestive heart failure in childhood cancer survivors, prompting evaluation of serum biomarkers to detect subclinical cardiac dysfunction.
Can serum biomarkers (BNP, NT-proBNP, cardiac troponins) detect subclinical anthracycline-induced cardiotoxicity in childhood cancer patients?
Can serum biomarkers (BNP, NT-proBNP, cardiac troponins) detect subclinical anthracycline-induced cardiotoxicity in childhood cancer patients?
Serum biomarkers like NT-proBNP show promise as sensitive predictors for anthracycline-induced cardiotoxicity and subsequent heart failure in childhood cancer patients.
Anthracyclines are routinely used in cancer chemotherapy in many childhood cancers. A serious adverse effect of doxorubicin chemotherapy is cardiotoxicity which may lead to congestive heart failure for long-term survivors years after treatment. Currently, echocardiography is used to control the heart function during anthracyclines therapy. B-type natriuretic peptide (BNP) and NT-proBNP as well as cardiac troponins have been proposed as clinical markers for subclinical anthracycline-induced cardiotoxicity. The BNP and pro-BNP can be easily measured in plasma and initial data indicate that the NT-proBNP could be sensitive predictor for the development of congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Attinà et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: